4
Changes in Ownership
Taysha Gene Therapies, Inc. Filed Acc 0001209191-21-044563
CMO and Head of R&D sold 79,000 shares at an average $22.63 ($1,787,936)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| PRASAD SUYASH CMO and Head of R&D | 2021-06-29 | Sale | −35,056 | $23.74 | $832,229 | 637,533 | D |
| PRASAD SUYASH CMO and Head of R&D | 2021-06-29 | Sale | −3,862 | $24.46 | $94,465 | 633,671 | D |
| PRASAD SUYASH CMO and Head of R&D | 2021-06-29 | Sale | −300 | $25.19 | $7,557 | 633,371 | D |
| PRASAD SUYASH CMO and Head of R&D | 2021-06-30 | Sale | −13,374 | $21.42 | $286,471 | 619,997 | D |
| PRASAD SUYASH CMO and Head of R&D | 2021-06-30 | Sale | −6,202 | $22.44 | $139,173 | 613,795 | D |
| PRASAD SUYASH CMO and Head of R&D | 2021-06-30 | Sale | −500 | $23.70 | $11,850 | 613,295 | D |
| PRASAD SUYASH CMO and Head of R&D | 2021-07-01 | Sale | −19,706 | $21.12 | $416,191 | 593,589 | D |
| Open-market sales · 79,000 sh · avg $22.63 · $1,787,936 | |||||||
Loading xslF345X03/doc4.xml…